Table 3.
Yokoyama et al. (May 2014): Secondary Outcomes Summary21
| JTT-751 (n = 116) | Sevelamer HCl (n = 113) | Between-Group P Value | |||
|---|---|---|---|---|---|
| Baseline | End of Treatment | Baseline | End of Treatment | ||
| Serum iron (mcg/dL) | 52.5 | 81.5 | 63.0 | 58.0 | < 0.001 |
| Ferritin (ng/mL) | 48.2 | 123.0 | 66.9 | 54.7 | < 0.001 |
| TIBC (mcg/dL) | 249.0 | 226.5 | 241.0 | 261.0 | < 0.001 |
| TSAT (%) | 23.0 | 35.9 | 24.1 | 23.5 | < 0.001 |
| Hgb (g/dL) | 10.9 | 11.8 | 10.8 | 10.6 | < 0.001 |
| Hct (%) | 33.5 | 36.1 | 33.1 | 32.9 | < 0.001 |
HCl = hydrochloride; Hct = hematocrit; Hgb = hemoglobin; TIBC = total iron binding capacity; TSAT = transferrin saturation